Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4

Conditions

Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Tumor Malignancies 1Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Advanced or Recurrent Solid Tumors 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × vadimezan × Clear all
NCT01240642 2020-12-09

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Novartis

Phase 1 Terminated
27 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01278758 2020-12-09

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Novartis

Phase 1 Terminated
7 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01278849 2020-12-09

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Novartis

Phase 1 Terminated
5 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01299701 2017-02-14

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Novartis

Phase 1 Terminated
7 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡